focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIp Group Regulatory News (IPO)

Share Price Information for Ip Group (IPO)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 51.20
Bid: 51.20
Ask: 51.40
Change: -0.20 (-0.39%)
Spread: 0.20 (0.391%)
Open: 51.50
High: 52.10
Low: 51.10
Prev. Close: 51.40
IPO Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Portfolio company Hysata completes funding round

2 Aug 2022 07:00

RNS Number : 5253U
IP Group PLC
02 August 2022
 

FOR RELEASE ON

02 August 2022

 

IP Group plc - Portfolio company Hysata completes oversubscribed series A funding round to develop pilot manufacturing facility

 

IP Group plc (LSE: IPO) ("IP Group" or "the Group"), which develops world-changing science and technology businesses across life sciences, technology and cleantech, notes that portfolio company Hysata Pty Ltd ("Hysata" or "the Company") has raised $A42.5m (£24.3m*) to help develop a pilot manufacturing facility aimed at delivering the world's lowest cost green hydrogen.

Hysata, an Australian electrolyser company developing a completely new type of electrolyser featuring the world's most efficient electrolysis cell, launched last year having spun out of the University of Wollongong. The Hysata electrolyser operates at 95% system efficiency (41.5 kWh/kg), delivering a leap in performance and cost over incumbent technologies, which typically operate at 75% or less. This high efficiency, coupled with the simple approach to mass manufacturing and low supply chain risk puts the company on a path to delivering the world's lowest cost green hydrogen.

IP Group committed a total of A$19m (£10.9m*) to the funding round (A$9m(£5.1m*) from IP Group Australia and A$10m (£5.7m*) from our cleantech platform, Kiko Ventures). Following completion, the Group's stake in Hysata is valued at approximately £19.0m. IP Group has recorded a net unrealised fair value gain of approximately £8.4m.

Greg Smith, Chief Executive Officer of IP Group, said: "Hysata has made excellent technical progress with research in Nature Communications, the scientific journal, confirming its efficiency earlier this year and we're delighted to see Hysata attract such strong interest in this round. This is a great example of IP Group's model where our Australian team have worked closely with our cleantech team in the UK to find, fund and support this exciting hydrogen technology."

The full release follows below.

*GBP equivalent using 1.75 AUD/GBP

For more information, please contact:

 

IP Group plc

www.ipgroupplc.com

Liz Vaughan-Adams, Communications

+44 (0) 20 7444 0062/+44 (0) 7967 312125

Charlotte Street Partners

David Gaffney

+44 (0) 7854 609998

Andrew Wilson

+44 (0) 7810 636995

 

Notes for editors

 

About IP Group

 

IP Group develops world-changing science and technology businesses across life sciences, technology and cleantech (through Kiko Ventures). The Group has a strong track record of success, having been the founder investor in a number of high-profile companies including Oxford Nanopore Technologies plc, and has one of the most exciting portfolios of high-growth businesses in Europe. The Group also owns Parkwalk, the UK's largest growth EIS fund manager which backs world-changing technologies emerging from the UK's leading universities and research institutions. IP Group is listed on the Main Market of the London Stock Exchange under the code IPO.

 

For more information, please visit our website at www.ipgroupplc.com.

 

ENDS

 

Green hydrogen company Hysata's Series A funding exceeds $40 million 

 

The Clean Energy Finance Corporation, Kiko Ventures, IP Group Australia, Vestas Ventures, and Hostplus are among the top-tier investors supporting Hysata's Capillary-Fed Electrolyser

 

(Sydney, Australia) Tuesday 2 August 2022

 

Australian company Hysata's world-leading hydrogen electrolyser technology has been supported by renowned global investors, as the organisation closes its oversubscribed Series A funding round of $42.5 million AUD. Virescent Ventures led the funding round on behalf of the Clean Energy Finance Corporation (CEFC) (Aus), with participation from Kiko Ventures (UK), IP Group Australia, Vestas Ventures (Denmark), Hostplus (Aus) and BlueScope (via its ventures arm BlueScopeX TM) (Aus).

 

Assembling such a high profile and high impact list of investors underlines the significance of the transformation that Hysata is bringing to the green hydrogen industry. The Hysata electrolyser operates at 95% system efficiency (41.5 kWh/kg), delivering a giant leap in performance and cost over incumbent technologies, which typically operate at 75% or less. This high efficiency, coupled with the simple approach to mass manufacturing and low supply chain risk puts the company on a path to delivering the world's lowest cost green hydrogen.

 

Funding from the Series A round will be used to grow the Hysata team and develop a pilot manufacturing facility.

 

"Our mission is to redefine the economics of green hydrogen production through our innovative proprietary electrolyser technology. The support of this international syndicate of clean energy practitioners and investors validates our core technology and our approach to scaling and mass manufacture," said Paul Barrett, CEO of Hysata.

 

"Green hydrogen is a vital energy vector on the world's path to net zero, critical to decarbonising the hard-to-abate, yet vital, sectors of our economy such as steelmaking, heavy transport, and the chemical industry. The extensive end use cases for green hydrogen translate to a greater than trillion-dollar market opportunity.

 

"Over the last 12-18 months, Hysata has been interacting with dozens of major customers globally. The impact our efficiency and system simplicity delivers to customers' project economics truly moves the needle. We look forward to continuing to work with our shareholders and customers to bring this much needed technology to market as soon as possible."

 

The CEFC invested $10 million into the Series A funding round, building on its initial $750,000 investment in the early commercial development of Hysata's research. CEFC CEO Ian Learmonth said that backing a company like Hysata and its cutting-edge electrolyser technology is vital in helping to grow Australia's clean technology ecosystem.

 

"The CEFC is proud to continue our support for Hysata, which is set to be a major player in the global electrolyser industry. Green hydrogen will be essential to addressing the hardest to abate sources of emissions, and we're excited to see Australian ingenuity providing the technology solutions that will help this industry reach scale. The CEFC has a strong focus on hydrogen related investments through both our Innovation and Advancing Hydrogen Funds and we are delighted to see Hysata continue to advance hydrogen to help meet future energy needs and reduce emissions in more sectors of the Australian economy," Mr Learmonth said.

 

The CEFC investment is via its specialist Clean Energy Innovation Fund, which is managed by Virescent Ventures. Virescent Ventures Partner Blair Pritchard said: "Hysata continues to make rapid progress and we are pleased to support such an innovative company with an outstanding team. The continued growth of Hysata is an important pointer to the enormous potential of hydrogen to our net zero future."

Kiko Ventures' Founding Partner, Robert Trezona, said Hysata has real potential to become a major global clean technology player.

 

"Having assessed scores of electrolyser technologies in my 20 years in cleantech, Hysata's technology stands out as a true breakthrough. The company has redefined the core cell architecture for alkaline electrolysis, producing a practical and scalable solution with game changing efficiency. Hysata has the potential to be a globally significant company in the hydrogen economy and we look forward to supporting its growth, especially here in Europe." Dr Trezona said.

 

IP Group Australia's Managing Director, Michael Molinari, added: "Hysata have assembled a world-class team to bring their revolutionary capillary-fed electrolyser to market. We're proud to have supported the company from before inception at the University of Wollongong to now redefining the economics of green hydrogen with their electrolyser that is set to scale."

 

Todd O'Neill, CEO of Vestas Ventures, said: "As the venture capital arm of the world's leading renewable technology provider, Vestas Ventures foresees great potential in combining wind power with electrolysers for green hydrogen production. We are delighted to have been invited to invest in Hysata. Nurturing disruptive renewable technologies is central to our investment strategy and we look forward to following Hysata's success over the coming years."

 

BlueScopeXTM's General Partner, Michael Quinn, agreed that Hysata's technology could play a significant role in the development of commercially viable hydrogen production.

 

"BlueScopeXTM is pleased to be investing in Australian technologies coming out of our local communities, with Hysata being born in the Illawarra. Our industry requires smart, affordable technologies like Hysata's to help progress the broader goal of decarbonisation, and we are excited to be supporting them on their path to commercialisation," he said.

 

ENDS

 

About Hysata

Hysata is an Australian electrolyser company which is developing a completely new type of electrolyser, featuring the world's most efficient electrolysis cell coupled with a simplified balance of plant. Electricity makes up most of the cost of green hydrogen and therefore, the most efficient electrolyser will deliver the lowest cost hydrogen. The Hysata founding team comprises electrolyser industry veterans, with deep expertise in the design and scale-up of novel electrolysers. Building on that foundation we are growing a world-class engineering, manufacturing, and commercial team with a footprint on multiple continents. Backed by leading global investors, Hysata is moving rapidly towards manufacturing at the multi-gigawatt scale needed to address climate change. For more information visit www.hysata.com

 

About the CEFC

The CEFC has a unique mission to accelerate investment in Australia's transition to net zero emissions. We invest to lead the market, operating with commercial rigour to address some of Australia's toughest emissions challenges. We're working with our co-investors across renewable energy generation and energy storage, as well as agriculture, infrastructure, property, transport and waste. Through the Advancing Hydrogen Fund, we're supporting the growth of a clean, innovative, safe and competitive hydrogen industry. And as Australia's largest dedicated cleantech investor, we continue to back cleantech entrepreneurs through the Clean Energy Innovation Fund. With $10 billion to invest on behalf of the Australian Government, we work to deliver a positive return for taxpayers across our portfolio.

 

About Virescent Ventures

Virescent Ventures was born out of the Clean Energy Innovation Fund, part of the Clean Energy Finance Corporation. Virescent invests in pre-seed to late-stage growth capital, and makes investments that address the largest, hardest to abate sources of emissions. For more information visit www.virescent.vc

 

About Kiko Ventures

Kiko Ventures is a US$450m venture investor that supports transformative climate tech and is the world's first evergreen cleantech VC. Launched in 2022 by the FTSE 250 listed investment firm IP Group plc, Kiko Ventures was founded to create new possibilities for a regenerative future. It is a highly flexible investment platform using IP Group's balance sheet capital and aims to be a long-term partner to leading climate tech innovators.

For more information visit www.kiko.vc

 

About IP Group Australia

IP Group develops world-changing science and technology businesses across life sciences, technology and cleantech. The Group has a strong track record of success, having been the founder investor in a number of high-profile companies including Oxford Nanopore Technologies plc. In Australia and New Zealand, IP Group works in close partnership with the Go8 Universities and the University of Auckland to identify ground-breaking technologies rooted in hard science, which have the most promising commercial potential. IP Group is listed on the Main Market of the London Stock Exchange under the code IPO. For more information visit www.ipgroupanz.com

 

About Vestas Ventures

Vestas Ventures is the corporate venture capital arm of Vestas Wind Systems, the world's leading renewable technology provider. Vestas Ventures invests in startups that support Vestas' vision to be the global leader in sustainable energy solutions. For more information visit www.vestas.com/ventures

 

About Hostplus

Hostplus has grown to be one of the largest industry super funds in Australia. With over 1.5 million members, more than 269,000 employers and $86.6 billion in funds under management (as at 30 June 2022), our scale and ongoing growth allows for low member costs and a broad range of investment opportunities. 

 

For more information visit www.hostplus.com.au

 

About BlueScopeXTM

BlueScope is one of the world's leading manufacturers steel coated products and commercial steel buildings. BlueScope is publicly listed on the Australian Stock Exchange, with an approximate market cap of $10b and >14,000 employees globally.

 

BlueScopeXTM is the ventures arm of BlueScope, dedicated to investing in and accelerating start-ups and businesses developing technologies and solutions in the decarbonisation space, and efficiency improvements in the built environment. For more information visit www.bluescope.com

 

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAPBMRTMTBMBBT
Date   Source Headline
3rd Jan 202311:48 amRNSTotal Voting Rights
12th Dec 20224:58 pmRNSAGM post-meeting shareholder engagement update
7th Dec 20224:39 pmRNSHolding(s) in Company
5th Dec 20227:00 amRNSIstesso announces FDA Fast Track for MBS2320
2nd Dec 202211:38 amRNSPortfolio company funding leads to £36m gain
30th Nov 202210:41 amRNSTotal Voting Rights
21st Nov 20222:13 pmRNSLife sciences presentation postponed
2nd Nov 20223:51 pmRNSInvestor presentation on life sciences
1st Nov 20228:59 amRNSNotification of major holdings
31st Oct 20224:35 pmRNSDirector/PDMR Shareholding
27th Oct 20224:55 pmRNSPDMR Dealing – SAYE Exercise
24th Oct 20226:02 pmRNSHolding(s) in Company
14th Oct 20229:42 amRNSHolding(s) in Company
30th Sep 202210:39 amRNSTotal Voting Rights
21st Sep 20225:29 pmRNSHolding(s) in Company
20th Sep 20226:10 pmRNSDirector/PDMR Shareholding
15th Sep 20224:41 pmRNSInvestor presentation
14th Sep 20224:33 pmRNSFurther re Scrip Dividend
13th Sep 20226:00 pmRNSFurther re Interim Scrip Dividend
13th Sep 20227:01 amEQSIP Group Trust (IPO): Initiation — International investor in impactful innovation
7th Sep 20224:33 pmRNSDirector/PDMR Shareholding, SAYE scheme
31st Aug 20228:51 amRNSIstesso starts Phase 2b trial of MBS2320
30th Aug 202212:59 pmRNSCash acquisition of portfolio company Diurnal
18th Aug 20229:25 amRNSScrip Dividend Reference Price
11th Aug 202210:50 amRNSHolding(s) in Company
3rd Aug 20227:00 amRNSHalf-yearly results
2nd Aug 20227:00 amRNSPortfolio company Hysata completes funding round
13th Jul 20229:30 amRNSNotice of Results
30th Jun 20225:46 pmRNSRSP awards and Scrip Elections
29th Jun 20229:16 amRNSFurther re Scrip Dividend
22nd Jun 20227:00 amRNSLaunches ‘Kiko Ventures’ cleantech platform
16th Jun 202211:27 amRNSDirector/PDMR Shareholding
14th Jun 20227:00 amRNSAGM Statement
8th Jun 20227:30 amRNSTR-1
6th Jun 20228:14 amRNSScrip Dividend Reference Price
1st Jun 20223:23 pmRNSInvestor presentation; AGM arrangements
13th May 202212:43 pmRNSDirector Declaration
9th May 20225:21 pmRNSNotice of AGM, Annual Report
29th Apr 20223:46 pmRNSTotal Voting Rights
27th Apr 20226:16 pmRNSDirector/PDMR Shareholding
25th Apr 20226:09 pmRNSDBSP awards; Director/PDMR shareholding
5th Apr 20227:00 amRNSPortfolio company First Light achieves fusion
16th Mar 20227:00 amRNSAnnual Results
7th Mar 20228:00 amRNSPortfolio co Microbiotica completes £50m raise
2nd Mar 20229:19 amRNSNotice of Results
14th Feb 20227:00 amRNSPortfolio company Bramble raises £35m
14th Feb 20227:00 amRNSPortfolio co First Light completes $45m fund raise
28th Jan 20225:02 pmRNSTransaction in Own Shares
28th Jan 20227:00 amRNSTransaction in Own Shares
27th Jan 20227:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.